1086 Cetuximab in a randomized phase II trial as a single agent or in combination with irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing, irinotecan-refractory metastatic colorectal cancer (CRC).

Details

Language :

English

ISSN :

13596349

Volume :

1

Issue :

5

Database :

Supplemental Index

Journal :

EJC Supplements

Publication Type :

Academic Journal

Accession number :

17015209

Full Text :

https://doi.org/10.1016/s1359-6349(03)91112-8